Gansu Wuwei Heavy Ion Center - Carbon Ion Cancer Treatment

Professor Kohei Takizawa, a leading Japanese expert, has joined the Gastrointestinal Cancer Center of Wuwei Tumor Hospital in Gansu Province on a regular basis to support the development of its National Key Discipline. Through teaching high-difficulty surgeries, conducting seminars on cutting-edge technologies, and fostering international scientific collaboration, he aims to elevate the diagnosis and treatment standards for digestive system tumors in the Hexi Corridor region, driving the discipline from technical following to standard-setting.

On June 22, the "Silk Road IP Opportunities China" event kicked off at the Lanzhou campus of Gansu Wewei Cancer Hospital. Experience officers and media representatives from multiple countries visited a domestic heavy-ion therapy base, showcasing Gansu's achievements in medical science and innovation. Led by 50 experts, the initiative aims to establish a new highland for heavy-ion treatment and advance health cooperation under the Belt and Road Initiative.

On June 16, the High-Quality Development of Heavy Ion Therapy and Green Medical Care Model Promotion Conference was held in Guiyang. Gansu Province Wuwei Tumor Hospital showcased the breakthrough efficacy of heavy ion therapy in treating refractory tumors such as liver cancer and pancreatic cancer, leveraging its "dual-center" collaborative advantages. By partnering with insurance and aviation services to create a full-chain guarantee system, the hospital aims to make cutting-edge technology accessible to patients worldwide.

On June 14, the High-Quality Development Promotion Conference for Heavy Ion Therapy was held in Kunming. Leveraging the "Bragg Peak" effect, dual centers in Wuwei and Lanzhou have used precision technology to tackle difficult-to-treat cancers such as liver and pancreatic cancer. By innovating a model integrating medical care, insurance, and air transport, they are lighting up new hope for patients' lives.

On June 6, 2026, the "2026 Precision Radiotherapy · Leading the Frontier" conference was held at the Wuwei Heavy Ion Center. Focusing on cutting-edge technologies such as heavy ion therapy and CyberKnife, the event discussed clinical treatment strategies for tumors including lung cancer, while showcasing breakthroughs in domestic heavy ion technology and achievements in an integrated, full-chain diagnostic and therapeutic system.

Adenoid cystic carcinoma of the trachea is difficult to cure? The Wuwei Heavy Ion Center has introduced domestic heavy (carbon) ion technology to precisely target tumors while sparing surrounding healthy tissue. This offers a non-invasive and highly effective new solution for patients with surgical limitations, those unresponsive to conventional radiotherapy, and elderly individuals. With over 2,800 cases treated so far, this approach has significantly improved quality of life and opened a new chapter in airway tumor treatment.

The Wuwei Heavy Ion Center offers precise carbon ion therapy for malignant eye tumors, providing globe-salvaging and vision-preserving treatment options for conditions such as melanoma and adenoid cystic carcinoma. With a short treatment course and costs of approximately 130,000 RMB, this approach achieves non-invasive cure, avoiding enucleation while preserving ocular appearance and quality of life.

Based on real-world data from 24 laryngeal cancer patients treated at the Gansu Wuhui Heavy Ion Center, this study summarizes the efficacy of heavy (carbon) ion therapy in early-stage, advanced-stage, and recurrent laryngeal cancer. The data indicate that survival rates are comparable to international standards and significantly superior to traditional therapies. This approach is particularly suitable for patients requiring voice preservation or those ineligible for surgery, offering a new choice for precise, low-toxicity curative treatment.